Cargando…

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

BACKGROUND: Recent years have seen standardization of the anatomic definitions of pancreatic adenocarcinoma, and increasing utilization of neoadjuvant therapy (NAT). The aim of the current review was to summarize the evidence for NAT in pancreatic adenocarcinoma since 2009, when consensus criteria f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhir, Mashaal, Malhotra, Gautam K., Sohal, Davendra P.S., Hein, Nicholas A., Smith, Lynette M., O’Reilly, Eileen M., Bahary, Nathan, Are, Chandrakanth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634869/ https://www.ncbi.nlm.nih.gov/pubmed/29017581 http://dx.doi.org/10.1186/s12957-017-1240-2

Ejemplares similares

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma
por: Fei, Naomi, et al.
Publicado: (2021)

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior
por: Sahin, Ibrahim H., et al.
Publicado: (2018)

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study
por: Singh, Ritu R., et al.
Publicado: (2022)

Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature
por: Dhir, Mashaal, et al.
Publicado: (2014)

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

Poorly differentiated signet ring cell carcinoma of pancreas masquerading as chronic pancreatitis
por: Yepuri, Natesh, et al.
Publicado: (2018)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
por: Askan, Gokce, et al.
Publicado: (2021)

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma
por: Jain, Anish J., et al.
Publicado: (2023)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma
por: Limbu, Yugal, et al.
Publicado: (2021)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma
por: Hayashi, Akimasa, et al.
Publicado: (2020)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
por: Motoi, Fuyuhiko, et al.
Publicado: (2020)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
por: Kim, Hyung Sun, et al.
Publicado: (2021)

Role of dual anti-HER2 therapy before liver resection for rectal metastases
por: Dantu, Siva, et al.
Publicado: (2022)

Prognostic Estimator of Survival for Patients with Localized and Extended Pancreatic Ductal Adenocarcinoma
por: Gleason, Michael X., et al.
Publicado: (2013)

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2018)

Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies
por: Dhir, Mashaal, et al.
Publicado: (2016)

Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
por: Schorn, S., et al.
Publicado: (2018)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases
por: Galindo, José, et al.
Publicado: (2013)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

Duration of therapy for locally advanced pancreatic cancer: Does it matter?
por: Tuli, Richard, et al.
Publicado: (2020)

Pancreatic Cancer: BRCA Targeted Therapy and Beyond
por: Keane, Fergus, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age
por: Chao, David T., et al.
Publicado: (2018)

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2019)

Clinical Predictors of Locally Advanced Pathology in Esophageal Adenocarcinoma
por: Gomez Cifuentes, Juan David, et al.
Publicado: (2021)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
por: Zhang, Yun, et al.
Publicado: (2021)

Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?
por: Khakoo, Shelize, et al.
Publicado: (2021)

Ex‐vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy
por: Rossi, Gemma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_raf97v4nmniibt8gchhcu6sl7i